Missouri Child Psychiatry Access Project (MO-CPAP)
Objective: To improve outcomes of children with mental illness in Missouri by providing pediatricians with a same-day phone consultation with a child/adolescent psychiatrist.
Eligible Subjects: Primary care providers who provide behavioral health care for children and adolescents in Missouri's Eastern region.
Participation Requirements: Completion of post-call satisfaction surveys and quarterly surveys regarding satisfaction and experience of use; educational training and webinars are optional.
Participant Reimbursement: None.
Primary Investigator: Laine Young-Walker, MD, Associate Professor of Psychiatry and Division Chief, Child and Adolescent Psychiatry, University of Missouri School of Medicine.
Current Status: Recruiting and enrolling providers.
More Information: See Frequently Asked Questions or visit the study website.
New Tics Study
Objective: To compare children who go on to develop Tourette Syndrome with children whose tics have resolved.
Eligible Subjects: Children ages 5-10 years old with tics that started less than 12 months ago.
Participation Requirements: Up to 6 visits, including annual follow-ups, questionnaires & interviews, genetic testing (saliva sample), MRI scans.
Participant Reimbursement: Compensation for time and effort.
Primary Investigator: Kevin J. Black, M.D., Professor of Psychiatry, Washington University School of Medicine.
Current Status: Recruiting patients.
More Information: Visit the study website or contact Emily 314.362.2083 or Vicki 314.273.1876.
Oral Bacteria Extract (ORBEX) Study
Objective:To see if taking an Oral Bacterial Extract (ORBEX) can prevent or reduce wheezing illnesses in young children.
Hypothesis: Broncho-Vaxom® contains no live germs and is a mix of components of different germs that cause respiratory infections. It may work like an immunization to stimulate your child’s immune system in order to increase the body’s natural defenses against a wide number of germs that cause children to have respiratory illnesses.
Eligible Subjects: Children ages 5-17 months who are at risk of developing wheezing or asthma.
Participation Requirements: Participants will take Broncho-Vaxom® or a placebo by mouth once daily for 10 days each month for 2 years, and will have physical exams, blood tests, stool and nasal sample collections. Breathing tests will be performed as the children get older. Parents of these subjects will answer questionnaires about their child's medical history. Parents will also answer questions about their child's wheezing illnesses through a weekly check-in report and during telephone calls they receive in between study visits.
Participant Reimbursement: Eligible participants will receive physical exams, study medications, small toys and monetary compensation for each completed study visit.
Primary Investigators: Leonard B. Bacharier, M.D., Clinical Director, Division of Allergy, Immunology, and Pulmonary Medicine, Washington University School of Medicine.
Current Status: Recruiting patients.
More Information: Contact study coordinators at (314) 286-1173 or toll free at (866) 841-2273.
Objective: To evaluate the effectiveness of family-based treatment delivered by a trained interventionist located within pediatric practices compared to the care typically delivered by the family’s pediatrician for children with overweight or obesity.
Hypothesis: Family-based treatment will be an effective treatment strategy for childhood obesity in the primary care setting.
Eligible Subjects: Children aged 6-12 years with a BMI above the 85th percentile.
Participation Requirements: Participating patients and families must be willing to be randomized to usual or care or family-based treatment with 1-hour family session including a weigh-in and case management, followed by frequent office visits for up to 2 years.
Participant Reimbursement: Participating families can receive up to $250 over the course of their 2-year involvement in the study.
Principal Investigator: Denise Wilfley, M.D., Professor of Psychiatry (Child), Washington University School of Medicine.
Current Status: Enrolling patients.
More Information: Contact Julie Mallin at 314.286.0251 or Julie.email@example.com.
Objective: To determine the shortest duration of therapy needed to decrease the development of antimicrobial resistance and risk of antimicrobial toxicity.
Hypothesis: Short course (5 day) therapy is superior to standard course (10-day) beta-lactam therapy (amoxicillin, amoxicillin/clavulanate, cefdinir).
Eligible Subjects: Children aged 6 months to 6 years who have experienced early clinical improvement of pneumonia.
Participation Requirements: Participants must be willing to be randomized to usual care or the treatment group who will have 3 site visits (likely be in-home) where the study team will give instruction on medication and obtain vital signs and a physical assessment.
Participant Reimbursement: Benefits for patients and families include reducing adverse drug events experienced when taking antibiotics, potentially preserving the patients’ microbiome, and helping reduce the rate of antibiotic resistance.
Primary Investigator: Jason Newland, M.D., M.Ed., Professor of Pediatrics, Infectious Diseases, and Stephanie A. Fritz, M.D., M.S.C.I., Associate Professor of Pediatrics, Infectious Disease Washington University School of Medicine.
Current Status: Recruiting practices and patients.
More Information: Contact Dr. Newland at 314.477.5128 or 913.562.7736.
Staph Hygiene Intervention for Eradication (SHINE)
Objective: Staphylococcus aureus can be spread from person-to-person and infections often occur in multiple members of the same household. S. aureus can also exist on household surfaces for prolonged periods of time. The SHINE study is a comparative effectiveness trial to evaluate several decolonization strategies in patients with MRSA infection, their household contacts, and household environmental surfaces to interrupt transmission of S. aureus among household members and prevent S. aureus infections.
Hypothesis: The central hypothesis of this trial is that an integrated approach of periodic personal and household environmental hygiene will reduce MRSA transmission in households and subsequently decrease the incidence of skin and soft tissue infections (SSTI).
Eligible Subjects: Patients aged 2 months - 21 years with an active or recent skin infection caused by the Staph germ. All members of each household are asked to participate in the study.
Participation Requirements: The study team will come to the patient’s home for study visits 5 times over 9 months. The enrollment visit will last approximately 1.5 hours, and the following 4 visits will last approximately 1 hour.
Participant Reimbursement: Each participating household member will receive monetary compensation for their time totaling up to $120 for all 5 visits over the 9 month study.
Primary Investigator: Stephanie A. Fritz, M.D., M.S.C.I., Associate Professor of Pediatrics, Infectious Diseases, Washington University School of Medicine.
More Information: Visit the study website or contact the study team at 314.747.6296 or by email at SHINE@kids.wustl.edu.